A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions
While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hyp...
Gespeichert in:
Veröffentlicht in: | Circulation (New York, N.Y.) N.Y.), 2021-07, Vol.144 (2), p.159-169 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 169 |
---|---|
container_issue | 2 |
container_start_page | 159 |
container_title | Circulation (New York, N.Y.) |
container_volume | 144 |
creator | Figtree, Gemma A. Broadfoot, Keith Casadei, Barbara Califf, Robert Crea, Filippo Drummond, Grant R. Freedman, Jane E. Guzik, Tomasz J. Harrison, David Hausenloy, Derek J. Hill, Joseph A. Januzzi, James L. Kingwell, Bronwyn A. Lam, Carolyn S.P. MacRae, Calum A. Misselwitz, Frank Miura, Tetsuji Ritchie, Rebecca H. Tomaszewski, Maciej Wu, Joseph C. Xiao, Junjie Zannad, Faiez |
description | While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic “buckets.” Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased “omic” approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development. |
doi_str_mv | 10.1161/CIR.0000000000000981 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03756465v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33876947</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4837-f1b8e0da125cc1567105985bb661e3920d8a6613962b0757e9039223abf6967c3</originalsourceid><addsrcrecordid>eNpdkF9LwzAUxYMobk6_gUhefejMnyZpH0un22AoOH0OaZvaamZK0m747W2dTvG-5OZwzg_uAeASoynGHN-ky8cp-jtxhI_AGDMSBiGj8TEYD2IgKCEjcOb9a__lVLBTMKI0EjwOxRisE5gqY2BrYZK3tX2HpXXwXu_g3NhMGZg0jbMqr7QfPKlyRW23yuedUQ7Oaq-V13Dmuhe4tqYbCP4cnJTKeH3x_U7A893tU7oIVg_zZZqsgjyMqAhKnEUaFQoTlueYcYERiyOWZZxjTWOCikj1K405yZBgQseoVwlVWcljLnI6Add7bqWMbFy9Ue5DWlXLRbKSg4b6a3nI2Rb33nDvzZ313unyEMBIDn3Kvk_5v88-drWPNV220cUh9FPgL3dnTaudfzPdTjtZaWXa6otHERYBQQQjgSkKBknQTz5ufQ8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Journals@Ovid Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Figtree, Gemma A. ; Broadfoot, Keith ; Casadei, Barbara ; Califf, Robert ; Crea, Filippo ; Drummond, Grant R. ; Freedman, Jane E. ; Guzik, Tomasz J. ; Harrison, David ; Hausenloy, Derek J. ; Hill, Joseph A. ; Januzzi, James L. ; Kingwell, Bronwyn A. ; Lam, Carolyn S.P. ; MacRae, Calum A. ; Misselwitz, Frank ; Miura, Tetsuji ; Ritchie, Rebecca H. ; Tomaszewski, Maciej ; Wu, Joseph C. ; Xiao, Junjie ; Zannad, Faiez</creator><creatorcontrib>Figtree, Gemma A. ; Broadfoot, Keith ; Casadei, Barbara ; Califf, Robert ; Crea, Filippo ; Drummond, Grant R. ; Freedman, Jane E. ; Guzik, Tomasz J. ; Harrison, David ; Hausenloy, Derek J. ; Hill, Joseph A. ; Januzzi, James L. ; Kingwell, Bronwyn A. ; Lam, Carolyn S.P. ; MacRae, Calum A. ; Misselwitz, Frank ; Miura, Tetsuji ; Ritchie, Rebecca H. ; Tomaszewski, Maciej ; Wu, Joseph C. ; Xiao, Junjie ; Zannad, Faiez</creatorcontrib><description>While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic “buckets.” Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased “omic” approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/CIR.0000000000000981</identifier><identifier>PMID: 33876947</identifier><language>eng</language><publisher>United States: by the American College of Cardiology Foundation and the American Heart Association, Inc</publisher><subject>Cardiology and cardiovascular system ; Cardiovascular Diseases - drug therapy ; Drug Discovery - methods ; Human health and pathology ; Humans ; Life Sciences</subject><ispartof>Circulation (New York, N.Y.), 2021-07, Vol.144 (2), p.159-169</ispartof><rights>by the American College of Cardiology Foundation and the American Heart Association, Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4837-f1b8e0da125cc1567105985bb661e3920d8a6613962b0757e9039223abf6967c3</citedby><cites>FETCH-LOGICAL-c4837-f1b8e0da125cc1567105985bb661e3920d8a6613962b0757e9039223abf6967c3</cites><orcidid>0000-0003-0231-3724 ; 0000-0001-7456-1570 ; 0000-0002-6068-8041 ; 0000-0002-8610-0058 ; 0000-0002-5379-1614 ; 0000-0002-6801-1617 ; 0000-0003-1366-7958 ; 0000-0002-0011-6164 ; 0000-0002-2162-0458 ; 0000-0001-8556-9738 ; 0000-0002-5080-6083 ; 0000-0001-9404-8846 ; 0000-0001-5024-7085 ; 0000-0001-8215-6567</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,3687,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33876947$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-03756465$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Figtree, Gemma A.</creatorcontrib><creatorcontrib>Broadfoot, Keith</creatorcontrib><creatorcontrib>Casadei, Barbara</creatorcontrib><creatorcontrib>Califf, Robert</creatorcontrib><creatorcontrib>Crea, Filippo</creatorcontrib><creatorcontrib>Drummond, Grant R.</creatorcontrib><creatorcontrib>Freedman, Jane E.</creatorcontrib><creatorcontrib>Guzik, Tomasz J.</creatorcontrib><creatorcontrib>Harrison, David</creatorcontrib><creatorcontrib>Hausenloy, Derek J.</creatorcontrib><creatorcontrib>Hill, Joseph A.</creatorcontrib><creatorcontrib>Januzzi, James L.</creatorcontrib><creatorcontrib>Kingwell, Bronwyn A.</creatorcontrib><creatorcontrib>Lam, Carolyn S.P.</creatorcontrib><creatorcontrib>MacRae, Calum A.</creatorcontrib><creatorcontrib>Misselwitz, Frank</creatorcontrib><creatorcontrib>Miura, Tetsuji</creatorcontrib><creatorcontrib>Ritchie, Rebecca H.</creatorcontrib><creatorcontrib>Tomaszewski, Maciej</creatorcontrib><creatorcontrib>Wu, Joseph C.</creatorcontrib><creatorcontrib>Xiao, Junjie</creatorcontrib><creatorcontrib>Zannad, Faiez</creatorcontrib><title>A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic “buckets.” Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased “omic” approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.</description><subject>Cardiology and cardiovascular system</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Drug Discovery - methods</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Life Sciences</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF9LwzAUxYMobk6_gUhefejMnyZpH0un22AoOH0OaZvaamZK0m747W2dTvG-5OZwzg_uAeASoynGHN-ky8cp-jtxhI_AGDMSBiGj8TEYD2IgKCEjcOb9a__lVLBTMKI0EjwOxRisE5gqY2BrYZK3tX2HpXXwXu_g3NhMGZg0jbMqr7QfPKlyRW23yuedUQ7Oaq-V13Dmuhe4tqYbCP4cnJTKeH3x_U7A893tU7oIVg_zZZqsgjyMqAhKnEUaFQoTlueYcYERiyOWZZxjTWOCikj1K405yZBgQseoVwlVWcljLnI6Add7bqWMbFy9Ue5DWlXLRbKSg4b6a3nI2Rb33nDvzZ313unyEMBIDn3Kvk_5v88-drWPNV220cUh9FPgL3dnTaudfzPdTjtZaWXa6otHERYBQQQjgSkKBknQTz5ufQ8</recordid><startdate>20210713</startdate><enddate>20210713</enddate><creator>Figtree, Gemma A.</creator><creator>Broadfoot, Keith</creator><creator>Casadei, Barbara</creator><creator>Califf, Robert</creator><creator>Crea, Filippo</creator><creator>Drummond, Grant R.</creator><creator>Freedman, Jane E.</creator><creator>Guzik, Tomasz J.</creator><creator>Harrison, David</creator><creator>Hausenloy, Derek J.</creator><creator>Hill, Joseph A.</creator><creator>Januzzi, James L.</creator><creator>Kingwell, Bronwyn A.</creator><creator>Lam, Carolyn S.P.</creator><creator>MacRae, Calum A.</creator><creator>Misselwitz, Frank</creator><creator>Miura, Tetsuji</creator><creator>Ritchie, Rebecca H.</creator><creator>Tomaszewski, Maciej</creator><creator>Wu, Joseph C.</creator><creator>Xiao, Junjie</creator><creator>Zannad, Faiez</creator><general>by the American College of Cardiology Foundation and the American Heart Association, Inc</general><general>American Heart Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0003-0231-3724</orcidid><orcidid>https://orcid.org/0000-0001-7456-1570</orcidid><orcidid>https://orcid.org/0000-0002-6068-8041</orcidid><orcidid>https://orcid.org/0000-0002-8610-0058</orcidid><orcidid>https://orcid.org/0000-0002-5379-1614</orcidid><orcidid>https://orcid.org/0000-0002-6801-1617</orcidid><orcidid>https://orcid.org/0000-0003-1366-7958</orcidid><orcidid>https://orcid.org/0000-0002-0011-6164</orcidid><orcidid>https://orcid.org/0000-0002-2162-0458</orcidid><orcidid>https://orcid.org/0000-0001-8556-9738</orcidid><orcidid>https://orcid.org/0000-0002-5080-6083</orcidid><orcidid>https://orcid.org/0000-0001-9404-8846</orcidid><orcidid>https://orcid.org/0000-0001-5024-7085</orcidid><orcidid>https://orcid.org/0000-0001-8215-6567</orcidid></search><sort><creationdate>20210713</creationdate><title>A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions</title><author>Figtree, Gemma A. ; Broadfoot, Keith ; Casadei, Barbara ; Califf, Robert ; Crea, Filippo ; Drummond, Grant R. ; Freedman, Jane E. ; Guzik, Tomasz J. ; Harrison, David ; Hausenloy, Derek J. ; Hill, Joseph A. ; Januzzi, James L. ; Kingwell, Bronwyn A. ; Lam, Carolyn S.P. ; MacRae, Calum A. ; Misselwitz, Frank ; Miura, Tetsuji ; Ritchie, Rebecca H. ; Tomaszewski, Maciej ; Wu, Joseph C. ; Xiao, Junjie ; Zannad, Faiez</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4837-f1b8e0da125cc1567105985bb661e3920d8a6613962b0757e9039223abf6967c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cardiology and cardiovascular system</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Drug Discovery - methods</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Life Sciences</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Figtree, Gemma A.</creatorcontrib><creatorcontrib>Broadfoot, Keith</creatorcontrib><creatorcontrib>Casadei, Barbara</creatorcontrib><creatorcontrib>Califf, Robert</creatorcontrib><creatorcontrib>Crea, Filippo</creatorcontrib><creatorcontrib>Drummond, Grant R.</creatorcontrib><creatorcontrib>Freedman, Jane E.</creatorcontrib><creatorcontrib>Guzik, Tomasz J.</creatorcontrib><creatorcontrib>Harrison, David</creatorcontrib><creatorcontrib>Hausenloy, Derek J.</creatorcontrib><creatorcontrib>Hill, Joseph A.</creatorcontrib><creatorcontrib>Januzzi, James L.</creatorcontrib><creatorcontrib>Kingwell, Bronwyn A.</creatorcontrib><creatorcontrib>Lam, Carolyn S.P.</creatorcontrib><creatorcontrib>MacRae, Calum A.</creatorcontrib><creatorcontrib>Misselwitz, Frank</creatorcontrib><creatorcontrib>Miura, Tetsuji</creatorcontrib><creatorcontrib>Ritchie, Rebecca H.</creatorcontrib><creatorcontrib>Tomaszewski, Maciej</creatorcontrib><creatorcontrib>Wu, Joseph C.</creatorcontrib><creatorcontrib>Xiao, Junjie</creatorcontrib><creatorcontrib>Zannad, Faiez</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Figtree, Gemma A.</au><au>Broadfoot, Keith</au><au>Casadei, Barbara</au><au>Califf, Robert</au><au>Crea, Filippo</au><au>Drummond, Grant R.</au><au>Freedman, Jane E.</au><au>Guzik, Tomasz J.</au><au>Harrison, David</au><au>Hausenloy, Derek J.</au><au>Hill, Joseph A.</au><au>Januzzi, James L.</au><au>Kingwell, Bronwyn A.</au><au>Lam, Carolyn S.P.</au><au>MacRae, Calum A.</au><au>Misselwitz, Frank</au><au>Miura, Tetsuji</au><au>Ritchie, Rebecca H.</au><au>Tomaszewski, Maciej</au><au>Wu, Joseph C.</au><au>Xiao, Junjie</au><au>Zannad, Faiez</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>2021-07-13</date><risdate>2021</risdate><volume>144</volume><issue>2</issue><spage>159</spage><epage>169</epage><pages>159-169</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><abstract>While we continue to wrestle with the immense challenge of implementing equitable access to established evidence-based treatments, substantial gaps remain in our pharmacotherapy armament for common forms of cardiovascular disease including coronary and peripheral arterial disease, heart failure, hypertension, and arrhythmia. We need to continue to invest in the development of new approaches for the discovery, rigorous assessment, and implementation of new therapies. Currently, the time and cost to progress from lead compound/product identification to the clinic, and the success rate in getting there reduces the incentive for industry to invest, despite the enormous burden of disease and potential size of market. There are tremendous opportunities with improved phenotyping of patients currently batched together in syndromic “buckets.” Use of advanced imaging and molecular markers may allow stratification of patients in a manner more aligned to biological mechanisms that can, in turn, be targeted by specific approaches developed using high-throughput molecular technologies. Unbiased “omic” approaches enhance the possibility of discovering completely new mechanisms in such groups. Furthermore, advances in drug discovery platforms, and models to study efficacy and toxicity more relevant to the human disease, are valuable. Re-imagining the relationships among discovery, translation, evaluation, and implementation will help reverse the trend away from investment in the cardiovascular space, establishing innovative platforms and approaches across the full spectrum of therapeutic development.</abstract><cop>United States</cop><pub>by the American College of Cardiology Foundation and the American Heart Association, Inc</pub><pmid>33876947</pmid><doi>10.1161/CIR.0000000000000981</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-0231-3724</orcidid><orcidid>https://orcid.org/0000-0001-7456-1570</orcidid><orcidid>https://orcid.org/0000-0002-6068-8041</orcidid><orcidid>https://orcid.org/0000-0002-8610-0058</orcidid><orcidid>https://orcid.org/0000-0002-5379-1614</orcidid><orcidid>https://orcid.org/0000-0002-6801-1617</orcidid><orcidid>https://orcid.org/0000-0003-1366-7958</orcidid><orcidid>https://orcid.org/0000-0002-0011-6164</orcidid><orcidid>https://orcid.org/0000-0002-2162-0458</orcidid><orcidid>https://orcid.org/0000-0001-8556-9738</orcidid><orcidid>https://orcid.org/0000-0002-5080-6083</orcidid><orcidid>https://orcid.org/0000-0001-9404-8846</orcidid><orcidid>https://orcid.org/0000-0001-5024-7085</orcidid><orcidid>https://orcid.org/0000-0001-8215-6567</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 2021-07, Vol.144 (2), p.159-169 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_hal_primary_oai_HAL_hal_03756465v1 |
source | MEDLINE; American Heart Association Journals; Journals@Ovid Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Cardiology and cardiovascular system Cardiovascular Diseases - drug therapy Drug Discovery - methods Human health and pathology Humans Life Sciences |
title | A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A56%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Call%20to%20Action%20for%20New%20Global%20Approaches%20to%20Cardiovascular%20Disease%20Drug%20Solutions&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=Figtree,%20Gemma%20A.&rft.date=2021-07-13&rft.volume=144&rft.issue=2&rft.spage=159&rft.epage=169&rft.pages=159-169&rft.issn=0009-7322&rft.eissn=1524-4539&rft_id=info:doi/10.1161/CIR.0000000000000981&rft_dat=%3Cpubmed_hal_p%3E33876947%3C/pubmed_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33876947&rfr_iscdi=true |